Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for ARV-027 (PolyQ-AR Degrader) in Spinal And Bulbar Muscular Atrophy. The expected timing is based on the latest available company guidance and may change.
11/05/25:- Preclinical SBMA mouse and human muscle data; first-in-human Phase 1 trial planned for 2026. 02/24/26:- First-in-human Ph1 trial of oral polyQ-AR degrader ARV-027 initiated in healthy volunteers; enrollment ongoing. 05/12/26:- Ph1 healthy volunteer trial enrollment ongoing; preclinical SBMA mouse data presented showing polyQ-AR degradation, functional gains, and extended survival. 08/04/26:- SAD cohorts complete; MAD enrollment initiated; initial muscle AR-degradation data expected H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.